TEVANYSEPharmaceutical PreparationsUS GAAP · USD

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Ltd. is a biopharmaceutical company built around a large global generics platform and a portfolio of branded innovative medicines. It operates through three regional segments — the United States, Europe and International Markets — and also sells active pharmaceutical ingredients, provides contract manufacturing services, and licenses products through its Medis affiliate.

Kysy yhtiöstä
Liikevaihto17,3mrd USD
+4,3 %v/v
Liikevoitto (EBIT)2 157milj. USD
+811,9 %v/v
EBIT-marginaali12,5%
+14,3 %-yks.v/v
Nettotulos1 410milj. USD
+186,0 %v/v
Vapaa kassavirta1 649milj. USD
+32,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−505101520mrd USD2020: 16,7 mrd USD2020: EBIT −3,6 mrd USD20202021: 15,9 mrd USD2021: EBIT 1,7 mrd USD20212022: 14,9 mrd USD2022: EBIT −2,2 mrd USD20222023: 15,8 mrd USD2023: EBIT 0,43 mrd USD20232024: 16,5 mrd USD2024: EBIT −0,30 mrd USD20242025: 17,3 mrd USD2025: EBIT 2,2 mrd USD202517,32,2
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Teva Pharmaceutical Industries Limited

Liiketoiminta

Osuus liikevaihdosta
Generic medicines55 %

Off-patent prescription products sold across multiple dosage forms and therapeutic areas.

Innovative medicines25 %

Branded specialty therapies focused on CNS, migraine, MS, respiratory and oncology.

Biosimilars and OTC10 %

Biologic follow-on products and over-the-counter medicines sold in regional markets.

API and contract manufacturing5 %

Third-party active ingredient sales and manufacturing services.

Out-licensing and other activities5 %

Product licensing and affiliate-based commercialization activities.

Tuotteet

Raportoitu · osuus liikevaihdosta
84,6%9,0%FY2025100 %
  • Products84,6 %
  • Distribution Service9,0 %
  • License3,9 %
  • Other2,5 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Teva sells primarily to wholesalers, retail drug chains, mail-order distributors, managed care purchasing organizations and hospitals. Its customer base differs by product type: generics are sold into large purchasing channels with strong bargaining power, while innovative medicines are sold through specialty and pharmacy distribution channels serving patients with chronic or complex conditions.

U.S. retail drug chains and wholesalers

Buy large volumes of generic medicines and some branded products for broad pharmacy distribution.

Managed care and buying groups

Influence formulary access, rebates and pricing for U.S. medicines.

Mail-order and specialty distributors

Purchase chronic and specialty therapies such as CNS and migraine products.

Hospitals and healthcare institutions

Buy injectable, inhaled and other hospital-administered products.

International pharmacy and healthcare channels

Buy generics, OTC and branded medicines across Europe and other markets.

Strategia

Teva’s strategy centers on growing its innovative portfolio while using its generics platform, global scale and regional operating structure to support access and lifecycle management. The company also emphasizes capital allocation toward higher-value activities and operational simplification to improve execution, supply reliability and cost efficiency.

Expand innovative medicinesKeskipitkä aikaväli

Branded specialty products provide differentiation beyond commoditized generics.

Protect and refresh the generics portfolioLyhyt aikaväli

Generics remain the volume base and support broad market access.

Improve operating efficiencyLyhyt aikaväli

A simpler cost structure helps fund R&D and commercial execution.

Broaden geographic executionKeskipitkä aikaväli

Regional diversification reduces dependence on any single market.

Maantiede

Teva is headquartered in Israel and operates across 57 markets, with major commercial presence in the United States, Europe and International Markets. The United States and Europe are the most important operating regions, while manufacturing, R&D and commercial activities are distributed globally to support local market access and supply reliability.

Riskit

Teva is exposed to intense generic-drug competition, customer concentration and pricing pressure, especially in the United States where a few large buyers control much of the market. It also faces regulatory, litigation, cybersecurity and policy risks that can disrupt product approvals, commercialization and supply continuity.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Generic price erosion and competition1Customer concentration in the U.S.2Regulatory and compliance actions3Litigation and patent disputes4Cybersecurity and data security incidents5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Generic price erosion and competitionVaikutus: KorkeaTodennäköisyys: Korkea

    Off-patent medicines face frequent entry from rival manufacturers and rapid pricing pressure.

    Kohdistuu: Generic prescription medicines

  2. Customer concentration in the U.S.Vaikutus: KorkeaTodennäköisyys: Korkea

    A relatively small number of wholesalers, chains and buying groups account for a large share of sales.

    Kohdistuu: United States generics

  3. Regulatory and compliance actionsVaikutus: KorkeaTodennäköisyys: Korkea

    Pharmaceutical manufacturing and marketing are heavily regulated and noncompliance can trigger penalties or shutdowns.

    Kohdistuu: Global manufacturing and approvals

  4. Litigation and patent disputesVaikutus: KeskitasoTodennäköisyys: Korkea

    Product challenges, including COPAXONE-related disputes, can delay or limit commercialization.

    Kohdistuu: Selected branded products

  5. Cybersecurity and data security incidentsVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    IT disruption or data theft could interrupt operations and create liability.

    Kohdistuu: Global systems and third-party vendors

Kysy Clarifolta: Teva Pharmaceutical Industries Limited

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition and U.S. sales deductions

Gross sales are reduced by estimated rebates, chargebacks and allowances in the same period.

Vaikutus: Affects reported net revenue and comparability across quarters

Contingencies and litigation reserves

Product disputes and regulatory matters require judgment on probable losses.

Vaikutus: Can create volatile charges and balance-sheet liabilities

Impairment of property, plant and equipment

Manufacturing assets must be tested if utilization or economics weaken.

Vaikutus: May lead to non-cash write-downs

Income taxes

Deferred tax assets, valuation allowances and uncertain tax positions require estimates.

Vaikutus: Can materially change net income and equity

Hedging and foreign exchange

Regional operations and cross-border cash flows create currency exposure.

Vaikutus: Can affect operating results and comprehensive income

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

MediciNova, Inc

MNOV · Pharmaceutical Preparations

Veeva Systems Inc

VEEV · Services-Prepackaged Software

Takeda Pharmaceutical Company Limited

TAK · Pharmaceutical Preparations

Elite Pharmaceuticals Inc /NV/

ELTP · Pharmaceutical Preparations

SIGA Technologies Inc

SIGA · Pharmaceutical Preparations

Gilead Sciences, Inc

GILD · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026

Teva Pharmaceutical Industries Limited (TEVA) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo